Asana jumps 10% in trading debut after opening at $4.2 billion valuation

Spencer Platt/Getty ImagesAsana jumped as much as 10% in its first day of trading on Wednesday. The stock opened at $27 per share, 29% above its reference price of $21. The ensuing climb marked a 10% increase from the opening price. With 155 million shares outstanding, Asana sported a valuation of $4.6 billion at its peak after opening at $4.2 billion. Visit Business Insider's homepage for more stories. Asana jumped as much as 10% in its first day of trading on Wednesday, hitting a high of $29.79. Asana is a work management software company based out of San Francisco. The firm went public via a direct listing rather than the traditional IPO route. With a reference price of $21 per share, Asana opened at $27 per share in the first minute of trade, giving it a valuation of $4.2 billion. At its peak on Wednesday, Asana sported a valuation of $4.6 billion, based on about 155 million shares outstanding. Asana was founded in 2008 and markets a web and mobile application designed to help teams organize, track, and manage their work. The firm counts other software based companies like SmartSheet and Atlassian as its competitors.  Read more: BANK OF AMERICA: Buy these 29 high-quality value stocks primed to cash in on the economic recovery According to its S-1 filing, Asana  reported fiscal year 2020 revenue of $142.6 million, representing year-over-year growth of 86%. Net loss in fiscal year 2020 was $118.6 million, more than double from the prior year's loss of $50.9 million.  As of January 31, the company had over 1.2 million paid users. A direct listing differs from a traditional IPO in that a direct listing does not raise any money for the company going public. Instead, a direct listing allows employees and shareholders to cash out and sell shares. Asana isn't the only company going public via a direct listing today. Palantir is expected to To keep reading about Asana jumps 10% in trading debut after opening at $4.2 billion valuation, Click on the link. Seoul, Korea
http://dlvr.it/RhhHvM

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint